# DBV Technologies S.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/DBV Technologies S.A.). ## Overview DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform designed to deliver allergens through the skin. Its lead program, Viaskin Peanut, is being advanced for peanut allergy in children, with the company focused on late-stage clinical development, regulatory filings, and commercial readiness in the United States and Europe. ## Products & services • Viaskin Peanut epicutaneous patch • Viaskin patch platform for allergen immunotherapy • Clinical development for peanut allergy indications • Regulatory and BLA preparation services • Commercial launch readiness and supply-chain setup - **Viaskin Peanut program** (70%) — Lead product candidate for peanut allergy treatment using an epicutaneous patch. - **Viaskin platform development** (15%) — Broader patch-based allergy immunotherapy technology and related pipeline work. - **Clinical and regulatory activities** (10%) — Clinical trials, FDA/EMA interactions, and BLA/MAA preparation work. - **Manufacturing and supply readiness** (5%) — Third-party manufacturing, quality control, and pre-commercial supply commitments. - Viaskin Peanut epicutaneous patch - Viaskin platform for allergen immunotherapy - Late-stage clinical development programs - BLA and regulatory submission preparation - Commercial supply-chain and launch readiness ## Customers DBV does not sell a broad commercial product portfolio today; its primary end customers are patients with peanut allergy, especially children, if Viaskin Peanut is approved. In the current stage, the company’s main counterparties are regulators, clinical investigators, and manufacturing partners rather than paying end-users. Future commercial demand would come from physicians, allergy specialists, and healthcare systems that prescribe and reimburse the patch. - **Peanut allergy patients and caregivers** (primary) — Families seeking a non-oral immunotherapy option for peanut allergy, especially pediatric patients targeted by Viaskin Peanut. - **Allergy specialists and pediatric physicians** (primary) — Clinicians who would prescribe the patch if approved and drive adoption through treatment protocols. - **Regulators and health authorities** (primary) — FDA and EMA review the clinical package, safety data, and manufacturing readiness before approval. - **Clinical trial sites and investigators** (secondary) — Hospitals and research centers that enroll patients and generate efficacy/safety evidence. - **Manufacturing and supply partners** (secondary) — Third-party API and device manufacturers that enable clinical supply and future commercialization. - Children with peanut allergy are the intended end patients - Allergists and pediatric specialists would prescribe the therapy - Regulators buy into the program through clinical and filing review - Clinical trial sites support enrollment and data generation - Manufacturing partners supply API, patch components, and finished goods ## Geography The company is operationally split between the United States and Europe, with a primary U.S. office in Warren, New Jersey and additional North American facilities. Its active pharmaceutical ingredient for Viaskin Peanut is manufactured in France, and the company relies on European and other non-U.S. suppliers for critical raw materials and clinical inputs. Geography matters because regulatory strategy is centered on the U.S. BLA path and the European MAA path, while supply-chain exposure is concentrated in cross-border manufacturing and sourcing. - Primary U.S. office in Warren, New Jersey - Additional North American facilities support U.S. operations - Viaskin Peanut API is manufactured in France - Critical raw materials and lab inputs are sourced largely from Europe - U.S. and EU regulatory paths drive development and launch planning ## Strategy DBV’s strategy is to complete late-stage development of Viaskin Peanut, secure regulatory approval, and prepare for a U.S. launch if the program succeeds. The company is also strengthening manufacturing and supply arrangements with Sanofi and other partners so it can support commercial-scale production and reduce execution risk ahead of a potential approval. - **Complete late-stage clinical development** (short-term) — Positive pivotal data is needed to support regulatory submissions and commercial value creation. - **Prepare regulatory filings** (short-term) — BLA and potential EU submission are the gatekeepers to commercialization. - **Secure manufacturing and supply chain readiness** (medium-term) — Commercial launch requires reliable third-party production and inventory availability. - **Maintain liquidity through financing** (short-term) — The company is still pre-commercial and needs external capital to fund operations. - Advance VITESSE and related clinical studies to support approval - Prepare and submit a potential BLA for Viaskin Peanut - Build U.S. launch readiness before regulatory decision points - Lock in third-party manufacturing and supply capacity - Use financing and ATM proceeds to fund development and operations ## Risks DBV remains a pre-commercial biotech with substantial going-concern risk, so its value depends heavily on clinical success, regulatory approval, and access to capital. The company also depends on third-party manufacturing and cross-border sourcing, which creates supply-chain, tariff, and execution risk as it moves toward potential commercialization. - **Going-concern and liquidity risk** [critical] — The company disclosed substantial doubt about its ability to continue as a going concern due to operating losses and liquidity challenges. - **Clinical development failure** [high] — Viaskin Peanut depends on positive pivotal and supporting study results to justify filing and approval. - **Regulatory approval risk** [high] — The company needs FDA and potentially EMA acceptance of its clinical package and manufacturing readiness. - **Third-party manufacturing dependence** [high] — DBV does not own manufacturing facilities and relies on external suppliers for API and patch production. - **Tariffs and trade restrictions** [medium] — Cross-border sourcing of API, raw materials, and lab inputs could raise costs and disrupt timelines. - **Dilution from financing activities** [high] — ATM sales and warrant exercises can fund operations but may dilute existing shareholders. - Going-concern risk due to ongoing losses and liquidity needs - Clinical trial failure could delay or end Viaskin Peanut development - Regulatory setbacks could block BLA/MAA approval paths - Reliance on third-party manufacturing increases supply disruption risk - Tariffs and trade restrictions could raise costs and slow timelines - Future dilution risk from ATM sales and warrant exercises ## Accounting DBV’s results are shaped by judgment-heavy biotech accounting, especially clinical trial expense timing, supply commitments, and estimates around going-concern disclosures. Because the company is pre-revenue and relies on third-party manufacturing, purchase commitments, prepaid development costs, and potential loss contingencies can materially affect reported expenses and liquidity presentation. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Supply agreement commitments** — Can affect liabilities, R&D expense, and cash needs - **Going-concern disclosure** — Important for liquidity analysis and valuation - **Equity financing and warrant accounting** — Dilution and cash runway analysis - **Lease accounting and relocation costs** — Affects G&A expense and cash flow - Clinical trial and regulatory costs are expensed as R&D when incurred - Supply commitments may create take-or-pay obligations and future expense - Going-concern assessment affects disclosure and investor interpretation - ATM and warrant financing affect equity and dilution accounting - Lease and relocation costs influence G&A and cash flow timing --- *Last updated: 2026-04-28T20:00:22.346235+00:00*